Keyphrases
Next-generation Sequencing
100%
Bone Tissue
100%
Clinical Utility
100%
Soft Tissue Sarcoma
100%
Sarcoma
33%
Clinical Benefit
33%
Tumor
22%
Change in Treatment
22%
Treatment Options
11%
Genetic Modification
11%
Medical Records
11%
Soft Tissue
11%
Clinical Impact
11%
Clinical Practice
11%
Histological Subtypes
11%
Absence of Evidence
11%
Medical Treatment
11%
Metastatic Disease
11%
Recurrent Disease
11%
Metagenomic Next-generation Sequencing (mNGS)
11%
Molecular Profiling
11%
Systemic Chemotherapy
11%
Rare Tumors
11%
Mutational Burden
11%
Treatment Change
11%
Heterogeneous Tumors
11%
Actionable Alteration
11%
Actionable mutations
11%
Medicine and Dentistry
Bone Tissue
100%
Next Generation Sequencing
100%
Soft Tissue Sarcoma
100%
Neoplasm
30%
Connective Tissue Cancer
30%
Metastatic Carcinoma
10%
Gene Mutation
10%
Combination Therapy
10%
Recurrent Disease
10%
Hope
10%
Molecular Profiling
10%